Dec 02, 2019
Breckenridge Announces Final Approval of its ANDA for Rivastigmine Transdermal System (generic for Exelon® Patch)
Nov 12, 2019
Breckenridge Announces Final Approval of ANDA for Erlotinib Hydrochloride Tablets (generic for Tarceva®)
Mar 04, 2019
Breckenridge Announces Final Approval of its ANDA for Imatinib Mesylate Tablets (RLD: Gleevec®)
Feb 27, 2019
Breckenridge Announces Final Approval of its ANDA for Exemestane Tablets (Aromasin®)
Feb 12, 2019
Breckenridge Announces Tetracycline Capsules Launch
Oct 23, 2018
Breckenridge Announces Final Approval of its ANDA for Clobazam Tablets (Generic for Onfi®)
Oct 05, 2018
Breckenridge Announces Final Approval of its ANDA for Roflumilast Tablets (Daliresp®)
Jul 10, 2018
Breckenridge Announces Appointment of New President
May 29, 2018
Breckenridge Announces passing of its founder, Laurence D. (Larry) Runsdorf
Mar 27, 2018
Breckenridge Pharmaceutical, Inc. Announces Final Approval of its ANDA Entecavir tablets (Baraclude®)
Dec 04, 2017
Breckenridge Pharmaceutical, Inc. Announces Final Approval of its ANDA Megestrol Acetate Oral Suspension (Megace® ES)
Oct 03, 2017
Breckenridge Pharmaceutical, Inc. Announces Acquisition of 5 ANDA's
Sep 29, 2017
Breckenridge Pharmaceutical, Inc. and Impopharma, Inc. enter into licensing agreement
Sep 28, 2017
Impopharma Inc. and Breckenridge Pharmaceutical Inc. Enter Into an Asset-Purchase Agreement to Commercialize the Generic Version of a Leading Corticosteroid Product Upon FDA Approval
Jun 26, 2017
Breckenridge Pharmaceutical, Inc. Announces Final ANDA Approval for Azacitidine for Injection (Vidaza®)